Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious ...
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast ...
Pharmabiz9d
Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults
Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...
Pharmaceutical Technology10d
EC approves MSD’s pneumococcal 21-valent conjugate Capvaxive
MSD has received approval from the EC for Capvaxive, a pneumococcal 21-valent conjugate vaccine, to prevent invasive disease ...
Medical Dialogues10d
Merck Capvaxive gets European Commission nod for prevention of Invasive Pneumococcal Disease, Pneumococcal Pneumonia in adults
Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and ...
Merck (NYSE:MRK) Gains EC Approval For CAPVAXIVE® Amid Recent 7% Share Price Dip
Merck (NYSE:MRK) has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite ...
FiercePharma18d
Pfizer enlists Elizabeth Banks for Gen X-focused pneumococcal vaccine push
Currently available PCVs for the recommended age group include Pfizer’s Prevnar 20 and Merck’s Capvaxive. To get the word out about the expanded guidelines and the risk of pneumococcal disease ...